Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival

doi:10.4251/wjgo.v8.i3.248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10404)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

683

WORD

399

HTML

3784

Figures (1-1)

239

Tables (1-4)

230

Sum=5335

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

484

Download

1419

Sum=1903

Publishing Process of This Article

Item

Count

Browse

1160

Download

2006

Sum=3166

Mar 15, 2016 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248

Table 4 Ongoing neoadjuvant/borderline resectable trials

Trial	Registration No.	Treatment groups	Primary endpoint	Patients planned
NEONAX	NCT02047513	2 cycles Gem + nab-paclitaxel neoadjuvant	DFS	166
NEONAX	NCT02047513	4 cycles Gem + nab-paclitaxel adjuvant	DFS	166
		6 cycles Gem + nab-paclitaxel adjuvant
Perioperative mFOLFIRINOX	NCT02047474	3 cycles FOLFORINOX	DFS	46
Perioperative mFOLFIRINOX	NCT02047474	Neoadjuvant + adjuvant	DFS	46
NEOLAP	NCT02125136	2 cycles Gem + nab-paclitaxel	Conversion rate	168
		+ 2 × FOLFIRINOX		(including locally advanced PDAC)
		+ adjuvant 3 × Gem + nab-paclitaxel
		4 cycles Gem + nab-paclitaxel
		+ adjuvant 3 × Gem + nab-paclitaxel

DFS: Disease-free survival; PDAC: Pancreatic ductal adenocarcinomas.

Citation: Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257
URL: https://www.wjgnet.com/1948-5204/full/v8/i3/248.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.248